Supporting Information

Targeted delivery of HES5-siRNA with novel polypeptide-modified nanoparticles for hepatocellular carcinoma therapy

Yu Xia, Changbing Wang, Tiantian Xu, Yinghua Li, Min Guo, Zhengfang Lin, Mingqi Zhao and Bing Zhu*

Virus laboratory, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510120, China

* Address for Correspondence: Bing Zhu
Guangzhou Women and children's Medical center, No 318 Renminzhong road, Yuexiu District, Guangzhou, Guangdong, 510120, P. R. China
Tel +86 20 8133 0740
Fax +86 20 8188 5978
Email: zhubing2017@hotmail.com



Fig. S1 Agarose gel electrophoretogram showing siRNA protection by RGDfC-SeNPs for different time of incubation compared to siRNA exposed to 50% serum. Naked siRNA not exposed to serum was used as control.



Fig. S2 Effect of temperature or endocytic inhibitors on the internalizations of RGDfC-SeNPs@siRNA nanoparticles.



Fig. S3 The viabilities of Lo2 cell treated with RGDfC-SeNPs@siRNA after 48 h incubation.



Fig. S4 H&E analyses of heart, liver, spleen, lung and kidney after treatment with saline, RGDfC-SeNPs, lipofectamine 2000@siRNA or RGDfC-SeNPs@siRNA.